Relapsed or Refractory Hodgkin's Lymphoma (DBCOND0106780)

Identifiers

Synonyms

Relapsed or Refractory Hodgkin Lymphoma

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05300282	Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients	Atezolizumab Bendamustine Gemcitabine Vinorelbine	treatment	1 / 2	recruiting
NCT03440788	Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin	Brentuximab vedotin	Not Available	Not Available	unknown_status
NCT03618550	Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma	Doxorubicin Gemcitabine Pembrolizumab Vinorelbine	treatment	2	recruiting
NCT05883449	Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL	AFM-13 Cyclophosphamide Fludarabine Human interleukin-2	treatment	2	recruiting
NCT01965119	Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma	Ruxolitinib	treatment	2	completed
NCT01572519	A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma	No drug interventions	treatment	1	completed
NCT05896046	SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma	Retlirafusp alfa	treatment	1 / 2	recruiting
NCT01492088	Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma	Brentuximab vedotin	treatment	1 / 2	completed